Insider purchases have tapered off from their frenzied pace in late 2018, but here are three names where such buying is evident.
With market sentiment shifting it's time to protect capital until the action improves.
David Tepper's Appaloosa LP renews calls for changes at the top.
Allergan wants Botox licenses for pediatric patients.
The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
One of General Electric's biggest liabilities will be outlined on Thursday.
Can they finally put some points on the board?
One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.
The stalling in the market indices has fueled the pessimists, but there is still no notable selling taking place.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.